Search
for
Sort by
Research 781–810 of 1000+
- What is the appropriate indication for baricitinib in patients with alopecia areata? What prior options can be considered?
- What is the appropriate indication for baricitinib in patients with alopecia areata? What prior options can be considered?
- A Pilot Randomized Controlled Trial Comparing the Efficacy and Safety of Oral Tofacitinib Versus Methotrexate In Moderate-to-Severe Alopecia Areata
- High-Dose Baricitinib for Severe Alopecia Areata with Suboptimal Response to Conventional Therapy: A Real-World Assessment
- BH21 Efficacy and safety of oral Janus kinase inhibitors in the treatment of alopecia areata: a systematic review and meta-analysis
- P151 A multicentre real-world evaluation of ritlecitinib in severe alopecia areata: patient-reported outcome measures
- A Case Report on Siddha Medicines Parangipattai Chooranam Tablet (Internal), Palagarai Parpa Tablet (Internal) and Muthiyar Koondhal Ennai (External) in the Management of Puzhuvettu
- P165 Real-world experience of ritlecitinib for the treatment of alopecia areata from an alopecia clinic in a large tertiary dermatology centre
- P146 A multicentre retrospective study evaluating the real-world efficacy and safety of ritlecitinib in the treatment of alopecia areata
- BH31 Ritlecitinib for severe alopecia areata: does regional prescribing match national guidance?
- BH20 An unintended sequela of hair regrowth: severe Janus kinase inhibitor-associated acneiform eruption in alopecia areata
- Alopecia Areata With an FFA ‐Like Phenotype: Clinicopathologic Features and Treatment Outcomes in a Prospective Cohort
- Rapid Hair Regrowth in Localized Alopecia Areata Following Low-Dose Intralesional Corticosteroid
- Effectiveness and Safety Profile of Oral Tofacitinib in Alopecia Areata: An Observational Study from a Tertiary Hospital
- Case Report: Dupilumab induced sustained complete remission in a child with severe alopecia areata and markedly elevated IgE
- Limitations of Treatment-Induced Alopecia Grading Instruments in Evaluating Therapeutic Response
- Real‐World Efficacy and Safety of Tofacitinib for Patients With Alopecia Areata: A Retrospective Multi‐Center Cohort Study
- How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
- Efficacy and predictive markers of response to tofacitinib and baricitinib therapy in alopecia areata: A 52-week comparative cohort study
- AYURVEDIC MANAGEMENT OF ALOPECIA AREATA USING VIDDHAKARMA AS A PARA-SURGICAL PROCEDURE: A CASE STUDY
- Advancing Hair Loss Assessment in Alopecia Areata: The Mathematical Case for Centralised, Standardised Imaging
- Efficacy and safety of tofacitinib in patients with alopecia areata
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial
- Effectiveness of Abrocitinib in Adolescent Alopecia Areata: A Prospective Observational Pilot Study
- Effectiveness and safety of oral Janus kinase inhibitors in patients aged ≤12 with alopecia areata: a systematic review and meta-analysis
- Effectiveness and safety of oral Janus kinase inhibitors in patients aged ≤12 with alopecia areata: a systematic review and meta-analysis
- Pediatric Clinical Trial Program in Progress: A Phase 3 Study and Long-term Extension Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 years of Age With Severe Alopecia Areata
- Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis
- Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis